Page 45 - CIBEREHD-2015-eng

Research Groups
Most relevant scientific articles
hezode C., asselah T., reddy k.r., hassanein T., Beren- Guer m., fleisCher-sTePniewska k. eT al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): A randomised, open-label trial. The Lancet. 2015;385(9986):2502-2509.
Cerini f., González J.m., Torres f., PuenTe a., Casas m., Vinaixa C. eT al. Impact of anticoagulation on upper-gas- trointestinal bleeding in cirrhosis. A retrospective multi- center study. Hepatology. 2015;62(2):575-583.
BerenGuer m., GarCía-eliz m., BaiGuera C., PuoTi m.. Be- yond cure: Preventing and managing the complications of
Highlights
In 2015 the group has obtained and/or contin- ued 13 research projects with public and private funding: PI15/02010-M.Berenguer (78045,00€), 2013/0049,Exp.2013_004)-M.Berenguer (11689,82€), 2014/0430,P.I. Exp. 2014_0430_GILEAD_BERENGU- ER-M.Berenguer (49800,00€), PI13/01770–V.Aguilera (64130,00€), 2014/0055,P.I. Exp.2014_0055. V.Aguil- era (29821,60€), 2014/0234,P.I.Exp.2014_0234_SAC_ TOYA-V.Aguilera(9234,60€), Defining High Risk Variceal Bleeding: A Rational For The Use Of Early Tips In Acute Bleeding And Preventing Rebleeding-C.Vinaixa (Co- lab.M.Berenguer), 2012/0154,P.I.Exp.PI12/01262– Luis MartiBonmati (Colab.A.Rubín) (19965,00€), 2011/0421, P.I. Exp.2011_0421_PP_BERENGUER.-M. Berenguer, EHD14PLAT004–MariaButiFerrer (Colab. M.Berenguer) (68208,34€), ICI14/00367-R.Esteban- Mur(Colab.M.Berenguer)(231360,00€), 2013/0424, P.I. Exp. 2013_0424_PP_PRIETO-M.Prieto(58885,03€) y 2014/0671, P.I. Exp. 2014_0671_FOR_OMNIPREX_PRI- ETO-M.Prieto(9861,50€).
In addition, the group has won a RIO HORTEGA con- tract(Ref:2015/0137)(53,762.00€)and an award from the SETH that sponsored a stay of three months in a foreign center of excellence-Group UCSF Viral Hepa- titis(Norah Terrault), University of California, San Fran- cisco(9,000.00€)
During that year a total of 34 clinical trials were on- going and/ or approved. We enclose the protocol number, PI and financing obtained to date: M11-665 (M. Berenguer) (2.322,00€), MK-5172-059 (M. Beren- guer), M13-393 (M. Berenguer), IMI-TRI-2013-01 (M.
end-stage liver disease. Current Opinion in HIV and AIDS. 2015;10(5):355-360.
forns x., Poordad f., Pedrosa m., BerenGuer m., wede- meyer h., ferenCi P. eT al. Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia. Liver Inter- national. 2015;35(11):2358-2362.
BilBao i., salCedo m., Gómez m.a., Jiménez C., CasTroaG- udin J., faBreGaT J. eT al. Renal function improvement in liver transplant recipients after early everolimus conver- sion: A clinical practice cohort study in Spain. Liver Trans- plantation. 2015;21(8):1056-1065.
Berenguer), M12-999 (M. Berenguer) (29.976,00€), M13-102 (M. Berenguer), TMC435HPC3016 (M. Berenguer) (28.644,25€), VX950-HPC3006 (M. Beren- guer) (70.553,90€), JAN-HEP-2011-01 (M. Berenguer) (4.800,00€), WEUKSTV1115 (M. Berenguer) (2.200,00€), MSD-BOC-2012-01 (M. Berenguer) (7.125,00€), M13- 099 (M. Berenguer) (26.833,28€), GSK-ELT-2011-01 (M. Berenguer) (260,62€), M13-393 (M. Berenguer) (11.455,84€), VX-950-C211 (M. Berenguer) (4.480,20€), CIRROXABAN (M. Berenguer), 747-302(M. Berenguer), M14-726 (M. Berenguer), OCR002-HE209 (M. Berengu- er), ISTH2015 (M. Berenguer), REG-HEPE-2014-01 (M. Prieto), BIO-ZUT-2014-01 (M. Prieto), TMC435HPC2019 (M. Prieto), 1423M0634 (M. Prieto), VTI-210(M. Prie- to),MRG-TEN-2011-01(M. Prieto), REM-TEN-2011-01 (M. Prieto), AI444-026 (M. Prieto), AI447-028 (M. Prieto), CRAD001HES01 (M. Prieto), GS-US-320-0110 (M. Prie- to), GS-US-337-0124 (M. Prieto), E5501-G000-310 (M. Prieto), E5501-G000-310 (M. Prieto).
These studies have resulted in the publication of 26 sci- entific papers in international journals (2015), an award for the best comunication at a conference (1500€) and the publication of two book chapters.
The principal investigator is a member of the Board of ESOT and ILTS well as Deputy Editor of the journal Transplantation and has been a guest speaker on 20 occasions at international conferences besides partic- ipating in 3 national masters. Three researchers have submitted in 2015 their doctoral thesis.
Institution: Fundación para la Investigación del Hospital la Fe · Contact: Hospital Universitario de La Fe Avda. Fernando Abril Martorell, 106. 46009 Valencia.
CIBEREHD I Annual report 2015 I 45